Since KMI169 severely impairs proliferation of castration- and enzalutamide-resistant prostate cancer cells, the compound is a promising starting point for the development of clinical candidate KMT9 inhibitors empowering novel therapeutic strategies for the treatment of therapy-resistant prostate cancer. Here, HEMK2 is linked to prostate cancer.